Immune suppression resulting from prolonged chemoprophylaxis and potential drug-vaccine interaction were investigated within the context of a randomized placebo-controlled trial that compared daily primaquine or weekly chloroquine administration for malaria prevention. After 11 months of prophylaxis, adult male subjects received a tetanus-diphtheria (Td) vaccination. Prophylaxis continued 4 weeks longer. Anti-tetanus and anti-diphtheria antibody levels were measured by ELISA at baseline and at 1, 3, 7, and 14 months after Td vaccination. All groups were comparable at baseline. Immunization triggered significant increases in anti-tetanus and anti-diphtheria IgG levels over each group's pre-Td baseline levels and those of an unvaccinated control group. Geometric mean anti-tetanus titers (GMTs) in the primaquine group were significantly higher than those of the placebo group at 1, 3, and 14 months. Anti-tetanus GMTs in placebo and chloroquine groups declined over 14 months to levels comparable to those of unvaccinated controls, but levels in the primaquine group remained significantly higher than in controls.
Recent trials in Indonesia and Africa have generated new in the frequency, magnitude, or duration of these responses [5] . However, because protective immunity to tetanus is primarily if interest in primaquine for malaria chemoprophylaxis [1 -3] . In Indonesian men, a daily regimen of 0.5 mg of primaquine base not wholly determined by levels of neutralizing antibody and because antimalarials can inhibit antibody response to rabies per kilogram of body weight was well-tolerated and yielded protective efficacies against Plasmodium falciparum and Plas- [6, 7] , cholera, and typhoid vaccines [8] , we were most interested in the drug's effects on humoral responses to the Td modium vivax of ú90% [3] . In this year-long trial, primaquine was associated with enhanced lymphoproliferative responses vaccination. This study compared anti-tetanus and anti-diphtheria IgG responses evoked by the Td vaccine among groups to mitogens and antigens [4] . This unanticipated result prompted an in vivo immunization trial designed to further receiving primaquine, chloroquine, and placebo. reveal the immunomodulating effects of the drug or the malaria protection it conferred.
Materials and Methods A tetanus-diphtheria (Td) vaccination was administered to nents of this study have been described [2, 5] . Only 2 of 72 subjects Primaquine was associated with the highest initial post-Td rerecalled a previous immunization (ú10 years prior). None of the sponses of lymphocytes to tetanus, and no significant differsubjects had been in military service where there might have been ences were observed between primaquine and placebo groups greater likelihood of immunization. Primaquine (n Å 30), chloroquine (n Å 21), placebo (n Å 21), and control without prophylaxis (n Å 20) groups were comparable in terms of age (Ç30 years), weight (Ç50 kg), ethnicity (Javanese/Sundanese), and so- potential malaria-induced immune suppression. in the chloroquine and placebo groups were marginally higher than in the unvaccinated controls (P õ .04). The anti-tetanus Results GMT in the primaquine group at this time was marginally above that of the vaccinated placebo group (P Å .04) and Baseline IgG responses. Baseline anti-tetanus IgG resignificantly greater than that of the unvaccinated control group sponses in primaquine, chloroquine, and placebo groups were (P õ .001). comparable, with individual titers ranging from 0 to 0.44
In all vaccinated groups, the proportion of protective anti-IU/mL. Protective anti-tetanus titers were found in 47%, 52%, tetanus titers and the GMTs fell from the peak levels attained and 29% of the respective groups (figure 1, P ú .25). Anti-1 month post-Td. Relative to these peaks, end-point proportions tetanus geometric mean titers (GMTs) were 0.09, 0.09, and with protective titers declined significantly in primaquine 0.07 IU/mL, respectively (ANOVA, P Å .66). Individual base-(100% vs. 82%, P Å .03) and placebo (100% vs. 58%, P Å line anti-diphtheria IgG titers ranged from 0.02 to 5.28 IU/mL.
.001) groups. End-point proportions of subjects with protective Protective anti-diphtheria titers were found in 93%, 95%, and 100% of the primaquine, chloroquine, and placebo groups, titers in the placebo (58%) and chloroquine (67%) groups fell any postvaccination sample point (P ú .17). Despite falling significantly from the peak attained 1 month after Td vaccination, the end-point GMT of the primaquine group remained significantly higher than its baseline (P Å .004) or that of the unvaccinated control group (P Å .02). End-point GMTs for vaccinated placebo and chloroquine groups fell to levels comparable with their baselines (P ú .10) and that of the control (P ú .22). There was no significant difference between antitetanus GMTs calculated for the unvaccinated control group at any of the 5 time points (ANOVA, P Å .42).
Post-Td vaccination anti-diphtheria IgG responses (figure 2B
). Anti-diphtheria IgG titers 1 month after Td vaccination ranged from 1.7-to 257-fold greater than at baseline. Highest anti-diphtheria GMTs, measured 1 month after vaccination, were 27.23, 24.38, and 19.95 IU/mL for the primaquine, chloroquine, and placebo groups, respectively (ANOVA, P Å .64), and averaged 58-, 62-, and 46-fold higher than their respective baseline GMTs. Anti-diphtheria GMTs of the primaquine, chloroquine, and placebo groups were comparable to one another (P ú .26) but were significantly greater than their respective baseline GMTs (P õ .0001) and those of unvaccinated controls (P õ .0001) at each post-Td vaccination sample point. Antidiphtheria GMTs declined over time in each vaccinated group. A significant decline from the peak 1 month after Td vaccination was measured in the chloroquine group 7 months after vaccination (P Å .04) and in the primaquine and placebo groups 14 months after vaccination (P Å .02 and .03, respectively). In all 3 vaccinated groups, subjects that attained the highest anti-diphtheria titers 1 month after vaccination generally also registered the highest end-point titers (r Å 0.69 -0.84). There was no correlation between anti-diphtheria and anti-tetanus antibody levels following immunization (r Å 00.19 to 00.01). There was no significant difference between anti-diphtheria GMTs calculated for the unvaccinated control group at any of The results show that the attainment of protective anti-tetacontrol (n Å 8 -13).
nus antibody titers and the magnitude of anti-tetanus GMTs were routinely highest in the vaccinated primaquine group. This finding complements the strong in vitro lymphocyte responses to levels comparable to their respective pre-Td vaccination baseline levels (placebo, P Å .11; chloroquine, P Å .50), but against tetanus that were measured in this treatment group [5] . Of interest, there was no correlation between cellular and that of the primaquine group remained significantly above baseline (82% vs. 47%, P Å .03). At end point, the proportion humoral responses to tetanus: Men with the highest lymphoproliferative responses were equally likely to have either high of primaquine subjects with protective titers was significantly greater than that of the unvaccinated control group (82% vs.
or low anti-tetanus IgG titers. The heightened cellular and humoral responses observed in the primaquine group during the 43%, P Å .03), while proportions in placebo and chloroquinetreated groups were similar to that of the control (P ú .27).
time of prophylaxis may relate more to the immunostimulatory properties of the drug than to its ability to prevent malariaAnti-tetanus GMTs in the primaquine group exceeded those of the vaccinated placebo group at 3 (P Å .03) and 14 months induced immune suppression. While it seems clear that longterm primaquine use was not immunosuppressive, the mecha-(P Å .002) after Td vaccination. There was no statistical difference between GMTs of the placebo and chloroquine groups at nisms underlying its effect on cellular and humoral immunity / 9d46$$ju46 05-11-98 10:41:02 jinfa UC: J Infect are unclear and may relate to drug-induced leukocytosis or and duration of humoral immune responses following Td vaccihematopoiesis [10] .
nation. The initially high anti-tetanus and anti-diphtheria IgG Since no association has been shown between asymptomatic titers observed in primaquine users complement their cellular malaria infections and reduced primary or secondary responses responses against tetanus and may engender a more effective to tetanus immunization [11] , it is unlikely that undetected longer-lasting immunity. These results constitute an additional or subpatent malaria infections could account for the large measure of safety assurance to support regulatory agency evaludifferences in cellular and humoral response that we measured.
ation of primaquine for malaria prophylaxis. Unrecalled previous tetanus immunizations in our subjects and their chance clustering may have accounted for the significant
